Sunshine Biopharma
Fort Lauderdale, Florida, United States · Healthcare, Health Care
Sunshine Biopharma is a pharmaceutical company that focuses on researching and offering life-saving medicines across various therapeutic areas, including oncology and antivirals.
Key facts
- Headquarters
- Fort Lauderdale, Florida, United States
- Employees
- 44
- Industries
- Healthcare, Health Care
- Status
- Public (SBFM)
- Website
- www.sunshinebiopharma.com
- Company page
Recent activity at Sunshine Biopharma
- : Sunshine Biopharma closes $6 million public offering with potential additional $14.4 million from warrant exercises.
- : SEC 8-K (1.01): On October 8, 2026, Sunshine Biopharma Inc. entered into a Placement Agent Agreement with Aegis Capital Corp. for a best efforts public offering. The offering consists of 10,509,082 common units, each comprising one share of common stock and two Series D warrants. Additionally, 400,000 pre-funded units will be issued, with each including a pre-funded warrant and two Series D Warrants. The event signifies an important capital raising effort by the company, potentially impacting its financial position and strategic initiatives in the biopharmaceutical sector.
- : SEC 8-K (5.07): On September 15, 2026, Dr. Steve N. Slilaty, holding the majority of the voting power of Sunshine Biopharma Inc., approved a significant corporate governance action via written consent. The approval allows the Company’s board of directors to implement a reverse stock split of its common stock at a ratio of up to 1-for-20, with the board having discretion over whether or when to enact this split, and the specific ratio to be confirmed at a whole number up to 1-for-20. This decision is strategically important as it may help the Company to enhance its stock price and overall market appeal. The effectuation of this split is conditioned on the issuance of a definitive information statement, which is expected to take place 20 days post-approval.
- : SEC 8-K (8.01): On September 11, 2026, Sunshine Biopharma Inc. reported a reduction in the exercise price of the outstanding Series B Warrants to $1.2046 due to recent sales of common stock under the Company’s at-the-market offering. This adjustment allows warrant holders to exercise their warrants at a lower price, which may increase the attractiveness of the warrants and potentially generate additional capital for the company. The new exercise price is subject to further adjustments as specified in the Series B Warrants documentation, impacting the financial structure and strategic positioning of the company moving forward.
- : SEC 8-K (5.02): On August 25, 2026, Dr. Andrew Keller, a director of Sunshine Biopharma Inc., notified the Company that he will not be seeking or accepting reelection to the Board of Directors upon completion of his current term. His term will expire at the Company's next annual shareholder meeting. This announcement indicates a notable change in corporate governance and may impact the board's composition and strategic direction moving forward.
- : SEC 8-K (8.01): This filing pertains to the reduction of the exercise price of Sunshine Biopharma Inc.’s Series B Warrants to $1.2202, following recent sales of the Company's common stock under an at-the-market offering. The adjustment is subject to further changes as specified under the terms of the Warrants. This event reflects the company's ongoing capital-raising efforts and the impact of market conditions on warrant pricing. The effective date of this adjustment corresponds with the date of the filing on August 3, 2026.
- : SEC 8-K (1.01): On July 20, 2026, Sunshine Biopharma Inc. entered into an At-The-Market Issuance Sales Agreement with Aegis Capital Corp. Under this agreement, the Company may sell shares of its common stock for up to $4,000,000 in aggregate offering price. Sales can be made through the Nasdaq Capital Market or any other trading market, with Aegis receiving a 3.0% commission on any gross proceeds. The Company is not obligated to conduct sales, and the Sales Agreement contains conditions under which either party may terminate it. This agreement is significant as it facilitates capital raising for the Company, impacting its liquidity and funding strategy.
- : SEC 8-K (1.01): On July 8, 2026, Sunshine Biopharma Inc. and its wholly-owned subsidiary, Nora Pharma Inc., entered into a Release Agreement with Malek Chamoun, the former president of Nora. As part of this agreement, Sunshine Biopharma agreed to pay Mr. Chamoun CAD$1,500,000 (approximately US$1,058,565) to settle a dispute between the parties. The terms of the settlement and the full text of the Release Agreement are included as an exhibit with the filing. This agreement has significant implications as it resolves ongoing litigation and allows the company to move forward without further disputes related to Mr. Chamoun’s tenure.
- : SEC 8-K (1.01): On May 18, 2026, Sunshine Biopharma Inc. entered into a Placement Agent Agreement with Aegis Capital Corp. for a best efforts public offering. This offering includes 11,160,000 Common Units at $0.50 each, comprising shares of Common Stock and Series C Warrants, and 840,000 Pre-Funded Units at $0.49999 each, which include Pre-Funded Warrants and Series C Warrants. The Offering closed on May 19, 2026, generating gross proceeds of approximately $6 million before fees and expenses. The transaction is significant as it will enhance the company's capital structure and market position, aligning with Nasdaq Capital Market regulations regarding stockholder approval for potential adjustments related to share combinations.
- : SEC 8-K (8.01): On March 6, 2026, Sunshine Biopharma Inc. entered into an engagement agreement with Aegis Capital Corp. to act as the Company’s warrant solicitation agent for a term of three months. This agreement is structured on a 'best efforts' basis to induce the exercise of the Company's outstanding warrants. Sunshine Biopharma agreed to pay Aegis a fee of 10% of the gross proceeds from any exercised warrants during this period and to reimburse certain expenses incurred by Aegis. This engagement is expected to enhance the Company's ability to capitalize on its outstanding warrants, thereby improving its capital position.
Sunshine Biopharma funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2026 | Post-IPO Equity | $6.0M |
| May 2023 | Seed | $5.0M |
| Apr 2022 | Venture | $19.5M |
| Mar 2022 | Venture | $8.0M |
Leadership
- Steve Slilaty, Executive Officer, Director
- Abderrazzak Merzouki, Executive Officer, Director
- Rabi Kiderchah, Director
- David Natan, Director
- Andrew Keller, Director
- Michel Roy, Chief Commercial Officer
- Camille Sebaaly, Executive Officer
Verified email and direct lines for Sunshine Biopharma’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Sunshine Biopharma in the news
- An oral drug candidate suppressed lung virus in infected mice - Stock Titan (Sep 16, 2026)
- Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing - Yahoo Finance (May 28, 2026)
- Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin - Yahoo Finance (May 21, 2026)
- Sunshine Biopharma, Inc. (SBFM) Company Information - Simply Wall St (Aug 08, 2022)
- Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies - ACCESS Newswire (Sep 16, 2026)
- Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue - Yahoo Finance (Oct 20, 2022)
- Sunshine Biopharma, Inc. (SBFM) Company Profile & Facts - Yahoo Finance - Yahoo! Finance Canada (May 15, 2017)
Companies similar to Sunshine Biopharma
- CorVent Medical · Healthcare, Health Care
- Materna Medical · Healthcare, Health Care
- Huxley Medical, Inc. · Healthcare, Health Care
- Cooler Heads Care · Healthcare, Health Care
- ImmuCell · Healthcare, Health Care
About Sunshine Biopharma: questions and answers
What does Sunshine Biopharma do?
Sunshine Biopharma is a pharmaceutical company that focuses on researching and offering life-saving medicines across various therapeutic areas, including oncology and antivirals.
Where is Sunshine Biopharma headquartered?
Sunshine Biopharma is headquartered in Fort Lauderdale, Florida, United States.
How many employees does Sunshine Biopharma have?
Sunshine Biopharma has about 44 employees.
Has Sunshine Biopharma raised funding?
Yes. Fundz has recorded 4 funding events for Sunshine Biopharma. The most recent, Post-IPO Equity of $6.0M, was in Oct 2026.
What is the latest news on Sunshine Biopharma?
On Oct 09, 2026, Sunshine Biopharma closes $6 million public offering with potential additional $14.4 million from warrant exercises.
Is Sunshine Biopharma a public company?
Yes. Sunshine Biopharma is publicly traded under the ticker SBFM.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy